6月24日，Abivax S.A.盘中下跌5.15%，报82.65美元/股，成交额7880.38万美元。
消息面上，公司核心药物obefazimod三期ABTECT维持试验此前因50mg组出现多例癌症病例，股价自130美元附近暴跌至约70美元，跌幅一度近50%。此后市场部分投资者认为癌症病例更可能与患者年龄相关，前期反应或过度，股价一度反弹至100美元上方。当前股价再度回落，显示市场对安全性争议的分歧尚未完全消化，技术性反弹动能减弱。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.